A Double-blind, Randomized, Vehicle-controlled, Parallel-group, Phase II Dose-ranging Study to Evaluate the Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2017
At a glance
- Drugs SR T100 (Primary)
- Indications Warts
- Focus Therapeutic Use
- Sponsors G&E Herbal Biotechnology
- 31 Jul 2017 Planned initiation date changed from 1 May 2016 to 1 Jun 2016.
- 31 Jul 2017 Status changed from not yet recruiting to withdrawn prior to enrolment due to budget issue.
- 20 Jun 2014 According to ClinicalTrials.gov record, the age group was changed from 6 years and above to 17 years and above.